Literature DB >> 2435037

Tissue polypeptide antigen (TPA) in pleural effusions.

F Parazzi, B Faravelli, L Gallo, M Nosenzo, A Razzetti, D Barone, R Bandelloni, E D'Amore.   

Abstract

The usefulness of tumor marker assay in pleural effusions for differential diagnosis is still debated. From the observation of common antigens on tissue polypeptide antigen (TPA) and keratins 8, 18 and 19 and vimentin, all substances contained in normal and neoplastic mesothelium, we felt it opportune to evaluate the use of TPA assay in 105 pleural effusions (46 benign and 59 malignant). The values were much higher than those found in blood. In hydrothorax the median value was 454 U/l (range, 59-1923), in exudative effusions 846 U/l (range, 258-4485), in metastatic pleural effusions 1277 U/l (range, 58-32352) and in mesotheliomas 7705 (range, 759-16000). The maximum value found in nonmalignant effusions was 4485 U/l; this value was taken as a cutoff level, so only 29.9% of the tumors were positive to the test. Our results showed this assay to be not very important for a differential diagnosis of malignant and nonmalignant pleural effusions. Nevertheless, the different TPA patterns in mesotheliomas (66.6% positive) and metastatic pleural effusions (15.9%) suggest that further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2435037     DOI: 10.1177/030089168707300106

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.

Authors:  G Salama; M Miédougé; P Rouzaud; M A Mauduyt; M C Pujazon; C Vincent; P Carles; G Serre
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

2.  Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report.

Authors:  Masatoshi Yamazoe; Hiromi Tomioka; Takahiro Kamada; Masahiro Kaneko; Eiji Katsuyama
Journal:  Respir Med Case Rep       Date:  2018-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.